<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Derazantinib &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/derazantinib/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Tue, 30 Dec 2025 10:05:49 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Derazantinib &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Derazantinib Boosts Gemcitabine by Blocking MUC5AC</title>
		<link>https://bioengineer.org/derazantinib-boosts-gemcitabine-by-blocking-muc5ac/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 30 Dec 2025 10:05:43 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Derazantinib]]></category>
		<category><![CDATA[Gemcitabine]]></category>
		<category><![CDATA[İşte içerik için uygun 5 etiket: **Combination therapy]]></category>
		<category><![CDATA[MUC5AC]]></category>
		<category><![CDATA[Pancreatic ductal adenocarcinoma (PDAC)** **Açıklama:** 1. **Combination therapy:** Makalenin ana teması Derazantinib ve Gemcitabine'in birlikte kullanımının etkinliğini artırmasıdır. 2. **Deraz]]></category>
		<guid isPermaLink="false">https://bioengineer.org/derazantinib-boosts-gemcitabine-by-blocking-muc5ac/</guid>

					<description><![CDATA[In a groundbreaking advance that could reshape the therapeutic landscape of pancreatic ductal adenocarcinoma (PDAC), researchers have unveiled how the drug Derazantinib significantly enhances the effectiveness of gemcitabine, a standard chemotherapy agent. This discovery centers around Derazantinib’s ability to suppress key signaling pathways—namely NF-κB and MAPK—that are known to drive cancer cell survival and drug [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">312337</post-id>	</item>
	</channel>
</rss>
